LUCID DIAGNOSTICS INC. LUCD 深 沪
等待开盘 09-19 09:30:00 美东时间
1.07
0.000
0.00%
华盛通- 最 高1.09
- 今 开1.07
- 成交量 107.29万股
- 最 低 1.05
- 昨 收 1.07
- 总市值 1.42亿
- 52周最高 1.80
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 0.7501
- 委 比 -69.28%
- 总股本 1.33亿
- 历史最高 13.52
- 量 比 0.69
- 振 幅 3.74%
- 历史最低 0.6301
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Lucid Diagnostics dips after pricing $25M stock offering
Lucid Diagnostics (NASDAQ:LUCD) fell over 17% premarket on Wednesday after it priced a public offering of 25 million shares at $1.00 each. Underwriters also have a 30-day option to buy up to 3.75 mill...
09-10 20:29
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 7.7% to $2...
09-10 05:06
Lucid Diagnostics Reveals Proposed Public Offering of Common Stock; Size Not Disclosed
NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.
09-10 04:02
BTIG Maintains Buy on Lucid Diagnostics, Raises Price Target to $2.5
BTIG analyst Mark Massaro maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $2 to $2.5.
09-05 18:32
Lucid Diagnostics Non-GAAP EPS of -$0.10
Lucid Diagnostics press release (NASDAQ:LUCD): Q2 Non-GAAP EPS of -$0.10. Processed 2,756 EsoGuard tests and recognized revenue of $1.2 million, ending quarter with over $30 million in pro forma cash ...
08-13 20:28
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
PAVmed gets 180-day extension to regain Nasdaq listing compliance
PAVmed (NASDAQ:PAVM) has been granted a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under the Nasdaq listing rule. The company now has until January 19, 2026 to...
07-30 20:16
Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG
Lucid Diagnostics' (NASDAQ:LUCD) EsoGuard test could get Medicare coverage soon, according to recent commentary from BTIG analysts. Analysts at BTIG said that during a day of investor meetings with L...
07-29 02:36
Lucid Diagnostics, a PAVmed Subsidiary, Nears Medicare Decision on EsoGuard Cancer Test
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that on
07-16 19:35
